CSU researchers are working on a coronavirus vaccine candidate – known as SolaVAX – which repurposes a commercial platform that is currently used to inactivate pathogens in blood transfusions. The strategy uses light and riboflavin to produce an inactivated virus which stimulates a person’s immune system to fight the virus.
Full story:
